Madina Karimova

Madina Karimova

Auto-generated profile, based on publicly available information

Madina Karimova


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
AGAnastasia Ganina
Anastasia Ganina
MAManarbek Askarov
Manarbek Askarov
LKLarissa Kozina
Larissa Kozina
MKMadina Karimova
Madina Karimova
YSYerzhan Shayakhmetov
Yerzhan Shayakhmetov
ABAbay Baigenzhin
Abay Baigenzhin
This review explores the significance and prospects of using diverse T-cell variants in the context of combined therapy for lung cancer treatment. Recently, there has been an increase in research focused on understanding the critical role of tumor-specific T lymphocytes and the potential benefits of autologous T-cell-based treatments for individuals with lung cancer. One promising approach involves intravenous administration of ex vivo-activated autologous lymphocytes to improve the immune status of patients with cancer. Investigations are also exploring the factors that influence the success of T-cell therapy and the methods used to stimulate them. Achieving a comprehensive understanding of the characteristics of activated lymphocytes and deciphering the mechanisms underlying their activation of innate anti-tumor immunity will pave the way for numerous clinical trials and the development of innovative strategies for cancer therapy like combined immunotherapy and radiation therapy.

31 October 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
AGAnastasia Ganina
Anastasia Ganina
MAManarbek Askarov
Manarbek Askarov
LKLarissa Kozina
Larissa Kozina
MKMadina Karimova
Madina Karimova
YSYerzhan Shayakhmetov
Yerzhan Shayakhmetov
ABAbay Baigenzhin
Abay Baigenzhin
This review article explores the significance and prospects of using diverse T-cell variants in the context of combined therapy for lung cancer treatment. Recently, there has been an increase in research focused on understanding the critical role of tumor-specific T-lymphocytes and the potential benefits of autologous T-cell-based treatments for individuals with lung cancer. One promising approach involves intravenous administration of ex vivo-activated autologous lymphocytes to improve the immune status of patients with cancer. Investigations are also exploring the factors that influence the success of T-cell therapy and the methods used to stimulate them. Achieving a comprehensive understanding of the characteristics of activated lymphocytes and deciphering the mechanisms underlying their activation of innate anti-tumor immunity will pave the way for numerous clinical trials and the development of innovative strategies for cancer therapy.

29 January 2026 in Geriatrics
Verified
Journal Article
Open access
PDF file
AGAnastasia Ganina
Anastasia Ganina
MKMadina Karimova
Madina Karimova
DIDana Idrissova
Dana Idrissova
ABAigul Brimova
Aigul Brimova
MAManarbek Askarov
Manarbek Askarov
LKLarissa Kozina
Larissa Kozina
Lung cancer is one of the most common malignant tumors and is associated with a high mortality rate, especially in aged patients. Immunotherapy is an effective method for treating lung cancer, particularly when used in combination with other treatments like chemotherapy. One of the types of immunotherapy is the use of autologous immune cells that are pre-activated before injection back to a patient. The effectiveness of this type of immunotherapy is determined by the specificity of its action on cancer cells through the activation of immune cell, e.g., lymphocytes. However, this treatment is not extensively used in elder patients due to higher risk of complications. On the other hand, in those aged patients who suffer from late stage cancer, the immune-cell based immunotherapy may come as a last resort. In this study, we present a clinical case of a 63-year-old patient with advanced-stage lung cancer and CT-confirmed infiltration of the left main bronchus. Treatment of the patient with immunotherapy using autologous activated lymphocytes combined with tomotherapy resulted in prominent improvement and decreased size of the malignancy. This positive effect was accompanied by a decrease in the number of circulating tumor cells in the blood. The patient was treated in May-June 2024 and is still alive with good condition as of August 2025. We conclude that combined treatment is a reliable option for selected aged patients with advanced-stage lung cancer.